10.3389/fphar.2020.600175 Summary Keywords anti-inflammatory effects, clinical applications, GLP-1RAs, liver injury, metabolic regulation Citation Hu Z, Tian D, Yang Z, Zhang J, Zhang L, Xu Y and Lu X (2026) The mechanisms of GLP-1 receptor agonists in liver diseases: their multifaceted impact on immune response and metabolic regulation
Subjects from the PIONNEER 7 study showed comparable satisfaction between oral semaglutide and sitagliptin [41], a dipeptidyl peptidase-4 inhibitor (DPP-4i) largely used in monotherapy or combination when first-line treatment does not achieve adequate glycaemic control, but sitagliptin does not provide any cardiovascular benefit [95]
The compound has one of the largest published research bases of any synthetic research peptide, with hundreds of peer-reviewed studies examining activity in wound healing, gastrointestinal protection, and nerve-injury models
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test may help provide context by revealing predispositions in GLP1R (rs6923761), GIPR (rs1800437), and other glucose-sensing variants
